Overview

A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX8394.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fore Biotherapeutics
Plexxikon